PROLOPRIM (trimethoprim) by Monarch Therapeutics is dihydrofolate reductase inhibitors [moa]. First approved in 1980.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
PROLOPRIM (trimethoprim) is an oral dihydrofolate reductase inhibitor approved in 1980 for bacterial infections. It works by inhibiting bacterial folate synthesis, preventing DNA replication in susceptible organisms. The drug is a foundational antibiotic with decades of clinical use.
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting contracting team size and transition-focused roles.
Dihydrofolate Reductase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers
Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
Worked on PROLOPRIM at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PROLOPRIM offers limited growth trajectory and smaller team dynamics typical of mature, generic-pressured products. Career value lies in operational expertise, cost optimization, and transition management rather than brand building or innovation.